anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In an abstract " A Bowel Care Survey to Assess Quality of Life in Persons With Spinal Cord Injury" in Journal of Spinal Cord Medicine in 2006, JP Lirio, et al surveyed 20 subjects (10 controls, 5 para, 5 tetra). The survey consisted of 42 items relating to GI function, bowel program/routine and quality of life. Survey items were weighted across a range of outcomes (e.g., complete continence=0 to frequent incontinence of solid evacuate=5). Total survey scores were compared among the groups by ANOVA with a Scheffe post hoc test. In those with SCI, level of injury (LOI) was converted to a numeric value and the relationship between LOI and total score was determined by simple regression.

The range of scores across the groups was 2 to 111 points. The controls scored significantly lower than those in the Para group who were significantly lower than those in the Tetra group (6 5 vs. 46 38 vs. 92 24, P\<0.01, respectively). Within SCI, 43% of the variance of the total score was explained by level of injury. (r2=42.5, P\<0.05), which is suggestive for the potential of good content validity of this tool. The authors concluded that the preliminary results of this survey show that persons with greater degrees of neurological impairment also manifest a greater negative impact from bowel care on their QoL. These results are encouraging for being able to develop a sensitive tool that will capture changes in bowel care status after therapeutic intervention that would be expected to influence QoL.

Innovative and potentially efficacious treatments for bowel care are being developed. There is a clinical/investigative need for a valid survey that is sensitive to quality of life (QoL) changes relating to interventions for bowel care in those with spinal cord injury (SCI). This is an ongoing project to develop a self-reported gastrointestinal (GI) survey that measures the impact of bowel function on QoL in individuals with SCI. This research seeks to develop a quality of life questionnaire that can be used to assess bowel function in able bodied individuals as well as spinal cord patients. This tool is essential for measuring change in bowel function due to an intervention or aging, rehabilitation, medications, etc.
Subjects in the experimental group will receive clinically prescribed meal plans designed to facilitate prolonged benign dietary ketosis (BDK) purposed at glucose regulation, improved insulin sensitivity and restored metabolic flexibility. Photobiomodulation therapy, via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
BACKGROUND: Septoria tritici blotch (STB), caused by the foliar fungus Zymoseptoria tritici, is one of the most damaging disease of wheat in Europe. Genetic resistance against this fungus relies on different types of resistance from non-host resistance (NHR) and host species specific resistance (HSSR) to host resistance mediated by quantitative trait loci (QTLs) or major resistance genes (Stb). Characterizing the diversity of theses resistances is of great importance for breeding wheat cultivars with efficient and durable resistance. While the functional mechanisms underlying these resistance types are not well understood, increasing piece of evidence suggest that fungus stomatal penetration and early establishment in the apoplast are both crucial for the outcome of some interactions between Z. tritici and plants. To validate and extend these previous observations, we conducted quantitative comparative phenotypical and cytological analyses of the infection process corresponding to 22 different interactions between plant species and Z. tritici isolates. These interactions included four major bread wheat Stb genes, four bread wheat accessions with contrasting quantitative resistance, two species resistant to Z. tritici isolates from bread wheat (HSSR) and four plant species resistant to all Z. tritici isolates (NHR).
RESULTS: Infiltration of Z. tritici spores into plant leaves allowed the partial bypass of all bread wheat resistances and durum wheat resistance, but not resistances from other plants species. Quantitative comparative cytological analysis showed that in the non-grass plant Nicotiana benthamiana, Z. tritici was stopped before stomatal penetration. By contrast, in all resistant grass plants, Z. tritici was stopped, at least partly, during stomatal penetration. The intensity of this early plant control process varied depending on resistance types, quantitative resistances being the least effective. These analyses also demonstrated that Stb-mediated resistances, HSSR and NHR, but not quantitative resistances, relied on the strong growth inhibition of the few Z. tritici penetrating hyphae at their entry point in the sub-stomatal cavity.
CONCLUSIONS: In addition to furnishing a robust quantitative cytological assessment system, our study uncovered three stopping patterns of Z. tritici by plant resistances. Stomatal resistance was found important for most resistances to Z. tritici, independently of its type (Stb, HSSR, NHR). These results provided a basis for the functional analysis of wheat resistance to Z. tritici and its improvement.
In dose escalation, patients will receive irinotecan and rucaparib. Irinotecan will be given once every 2 weeks (or 3 weeks if not tolerated) and rucaparib will be given twice daily for 7-14 days. Each cycle will be 28 days in duration unless we need to switch to the intermediate dosing regimen of every 21 days. Both rucaparib and irinotecan will be escalated.

In dose expansion, patients who have received prior PARP inhibitors will go straight to the combination arm of irinotecan and rucaparib. If patients are PARP inhibitor naïve, they can receive single agent rucaparib until progression. Once patients on single agent rucaparib progress, they can choose to go on the combination treatment arm. Patients will continue on treatment until disease progression or intolerable toxicity.
The abbreviated induction phase consists of 2 cycles of Ibrutinib + Rituximab and 2 cycles of Ibrutinib + R-CHOP for primary tumor reduction followed by CAR-T-cell treatment. In case of good clinical response (PR or CR) after 2 cycles of Ibrutinib + Rituximab, Ibrutinib + R-CHOP can be omitted. In this case, one cycle of Ibrutinib monotherapy will be applied. T cell apheresis will be performed after the initial 2 cycles. Application of KTE-X19 will be performed after lymphodepleting chemotherapy with Fludarabine and Cyclophosphamide (FC). After stable hematopoietic recovery, maintenance with Ibrutinib will be applied for 6 months but not prior to day 60 post CAR. The follow-up period starts after the completion of Ibrutinib maintenance and takes 4.5 up to 7 years.
A 6-deoxytetracycline of formula:  <FORM:0871423/IV (b)/1> is produced by catalytically reducing with hydrogen a tetracycline of formula:  <FORM:0871423/IV (b)/2> wherein R1 is hydrogen or methyl, R2 is hydrogen or hydroxy, R3 and R4 are hydrogen or dimethylamino with the proviso that both may not be hydrogen or dimethylamino and R5 is chlorine or bromine, R2 only being hydroxy when R1 is methyl, or an acid addition salt thereof, the reaction being carried out in a polar solvent solution in the presence of a noble metal catalyst and a substance capable of forming a chelate ring with a peri-dioxygenated hydronaphthalene, until approximately one molecule of hydrogen has been absorbed per mol of tetracycline.  A temperature of 0-100 DEG C. and pressure of 1/2 to 100 atmospheres is used.  The catalyst may be palladium or platinum especially suspended on a carrier.  The substances capable of forming a chelate ring may be boric acid, boron trihalides e.g. boron trifluoride, aluminium salts such as the chloride and magnesium salts such as the acetate.  The preferred reaction solvent is a mixture of water and dimethylformamide.  The 6-deoxytetracycline may be converted to (a) the acid salt by treatment with an acid at a pH below 4.0 e.g. sulphate, phosphate, oxalate, citrate, gluconate and trichloroacetate (b) the alkali metal and alkaline earth metal salt by treatment with the appropriate base to a pH above 6,0 (c) a metal complex of a metal salt such as aluminium gluconate and (d) the 4-epimer by maintaining a pH 3.0 to 5.0 and allowing to stand.  Specification 815,524 is referred to.
The exercises will be performed on the vibration platform but without vibration. Patients will be asked to hold a "body bar" corresponding to 10% of their body weight during exercises. 5 dynamics including squats (in 90 degrees knee extension), mini squats (120 degrees knee extension), mini squats on the toe tip (120 degrees knee extension), right and left lunge exercises, which will be accepted as 180 degrees full knee extension will perform an exercise protocol consisting of exercise. During the squat exercises, the patient will be positioned with their feet open at shoulder level and the knee flexion angle will be adjusted with a goniometer by the physiotherapist before each training session. For dynamic exercise, the duration will be 3 sets of 10 repetitions. Dynamic exercises will be performed with slow and controlled movements, consisting of 3 seconds of eccentric and 2 seconds of concentric phases.
Many anaesthesiology societies now recommend intake of clear fluids (water, tea or coffee without milk, juices without pulp) up to two hours before induction of anaesthesia for most patients undergoing elective surgery. This change the traditional practice of overnight fasting, while reducing thirst in the hours before surgery and seems to attenuate the response to the stress that results from a major operation, such as activation of endocrine and inflammatory systems which leads to tissue catabolism and insulin resistance. Among all the complications, one of the most frequent in patients undergoing mayor surgeries is undoubtedly paralytic ileus. The Enhanced Recovery After Surgery (ERAS) guidelines emphasize the importance of preventing this event. To prevent ileus, prokinetic agents such as metoclopramide are used, which although it has not been shown to shorten the period until the first flatulence or the first peristaltic movement, decrease nausea and vomiting. Chewing gum is another measure that is carried out, since it stimulates peristalsis and this measure if it had significant effects in time until first flatulence and in time until first peristaltic movement. In recent years there has been a great change in the perioperative management of patients who will undergo a radical cystectomy. The weight of traditional perioperative care has been an important barrier to the implementation of Fast Track (FT) protocols, since it is difficult to change a therapeutic strategy that has been carried out for decades. The positive results obtained in colorectal surgery led to Fast Track being implemented in other types of surgery similar to colorectal surgery such as radical cystectomy. Although there is apparently widespread enthusiasm for the implementation of Fast Track protocols, evidence of the use of this type of protocols in cystectomy is not robust, numerous studies claim that there is a big difference between the application of FT and the application of traditional measures in terms of length of hospital stay or complications. Because of this, more large-volume randomized experimental studies of patients are needed. This randomized double blind placebo-controlled trial of preoperative oral carbohydrate (CHO) treatment in patients undergoing elective radical cystectomy will investigate whether this treatment reduced the time of return of intestinal function. Secondary outcomes will be the incidence of infection of surgical wounds, the incidence of postoperative complications, the length of hospital stay and early postoperative fatigue in the three groups of patients undergoing this type of surgery.
BACKGROUND: Ischemic stroke remains the predominant contributor to mortality and disability globally. Microglia undergo rapid activation and initiate inflammatory cascade reactions by phenotypic polarization, participating in the regulation of inflammatory injury and tissue repair post-ischemic stroke. Regulating microglia-mediated neuroinflammation is a promising therapeutic strategy for ischemic stroke. Previously, we designed and synthesized a novel p55PIK inhibitor, TAT-N15 polypeptide, which presents inhibitive activity on NF-κB signaling-mediated inflammation in acute conjunctivitis and allergic rhinitis. The present study aimed to explore the therapeutic effect and mechanism of TAT-N15 on ischemia stroke.
METHODS: The mouse model of transient cerebral ischemia was made using the intraluminal filament method. After being treated with daily intraperitoneal injections of TAT-N15 (10 mg/kg) for 7 d, the neurological outcomes and the cerebral infarction volume were evaluated. Histopathology of the ischemia cerebral hemisphere was observed by H&E and Nissl staining. Neuronal survival, astrogliosis, and co-labeling of CD86/Iba1 and CD206/Iba1 were detected by immunofluorescence. The cell apoptosis was estimated by TUNEL staining. The expression levels of apoptosis-associated proteins, proinflammatory cytokines, protein markers of M1 and M2 microglia, and the phosphorylation of NF-κB and STAT3 proteins in the ischemic penumbra were detected by Western blot.
RESULTS: TAT-N15 treatment significantly decreased the infarct volume and alleviated neurological functional impairment, neuronal injury, and neuron apoptosis. Meanwhile, TAT-N15 treatment restrained the activation of microglia and astrocytes as well as the protein expression of proinflammatory cytokine in ischemic penumbra. Additionally, the administration of TAT-N15 treatment resulted in a significant reduction in the density of M1 phenotype microglia while concurrently increasing the density of M2 phenotype microglia within the ischemic penumbra. Finally, mechanical analysis unveiled that TAT-N15 exerted a substantial inhibitory effect on the protein expression of phosphorylated STAT3 and NF-κB.
CONCLUSION: TAT-N15 may inhibit neuroinflammation via regulating microglia activation and polarization through the STAT3/NF-κB pathway, which exhibits the neuroprotection effect in ischemic stroke.
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with INDOCIN has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.   
  
NSAIDs, including INDOCIN, may increase the risk of bleeding events. Co-morbid conditions, such as coagulation disorders, or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [ see Drug Interactions (7)].
Obesity has now become a severe and inescapable worry for people of all generations. Obesity is associated with an excessive or inappropriate fat build-up that poses a health concern. A BMI of 25 or above is considered to be overweight, while a BMI of 30 is classified as obese. In 2017, nearly 4 million individuals died as a direct result of being overweight and obese, according to the global burden of sickness report. Postural equilibrium is required for us to function normally in our daily lives. The ability to manage the center of mass inside the base of support, which serves to maintain the body in balance, is characterized as equilibrium. Balance is described as the process of maintaining the body center of gravity within its support base, which necessitates regular modifications given by muscle activity and joint alignment . 1. Thirtysix obese subjects from both gender with age ranging from 18-50 years old (Cruz-Gomez et al., 2021). And BMI ≥ 30 kg/m2. They will be selected from faculty of physical therapy Kafr Elshikh university Group A (exprimental group): 18 subjects received brain gym exercises for 15-30 minutes per day, three times a week, for eight consecutive weeks (Elbanna et al., 2023). And traditional treatment in form of balance training included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other. Periodic exercises were frequently performed for 45 min for 4 sessions per week for 8 weeks Group B (control group): 18 subjects will receive traditional treatment in form of balance training included standing on one leg, standing in tandem mode, walking in a tandem mode (one foot in front of the other), walking on toes and heels, side walk, standing while one upper extremity and the opposite lower extremity were up, rotating the head from side to side, walking backwards for four steps, and shifting weight from one foot to the other. Periodic exercises were frequently performed for 45 min for 4 sessions per week for 8 weeks
A process is disclosed for separating and collecting viable female spermatozoa (XX chromosome) and male spermatozoa (XY chromosome). The process utilizes apparatus comprising two sterilized columns of glass, plastic or other suitable material, a ball valve, a vacuum pump, a mercury manometer, and connecting tubes of glass, plastic or other suitable materials. The system is assembled with rubber percussion gaskets or other suitable connecting materials, to prevent the introduction of extraneous air into the closed system, and a burp bottle to preclude unwanted introduction of fluids into parts of the system under vacuum. The column containing the semen sample may be of variable volume, to accommodate semen samples of varying volume and concentration. The process may be modified by introducing into the system a direct and continuous electrical current flow, or by creating within the separating columns an electrophoretic field. The process may be further modified into a continuous-flow system by adding another mercury manometer, a Cartesian Diver regulator, a second burp bottle, and an over-flow collecting bottle connected to the two main columns.
Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day and the cells will be transduced with an in house designed CAR retroviral vector. Participants will receive daily intravenous (IV) infusion of lymphodepleting regimen of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. Participants will receive the CAR transduced T cells IV infusion in the BMT Inpatient Unit and remain admitted for close monitoring for at least the first 7 days following the cell infusion (D0 to Day +7), possibly longer if any side effects are encountered. The CAR transduced T cells will be escalated from 1 x 106 transduced T cells/kg (± 20%) to 2 x 106 transduced T cells/kg (± 20%) in a Phase I design, based on toxicity. Once discharged from the inpatient unit, for the next 7 days (Day +8 to Day +14) the patients will be evaluated in the High Dose Unit (labs and physical exam) to screen for toxicities.
The invention relates to a preparation method of tetra-palladium complexes in a crossed structure which synthesize tetrapyridylporphine bridge by using supramolecular self-assembly. The tetra-palladium complexes are possibly used for treating human cancers. The MTT experiment data indicates that the compounds have high antitumor activity. A single-teeth platinum ligand, of which the chloride ion is substituted by nitrate, and a bridging ligand tetrapyridylporphine are subjected to self-assembly, thereby obtaining new potential anticancer drugs with excellent anticancer activity and tumor targeting property. The complexes have excellent tumor cell targeting property, and induce the G-rich sequence of the cancer gene to form a G-quadruplex structure, thereby inhibiting the activity of the telomere enzyme and further having high antitumor activity. In addition, since the preparation method is simple and easy to implement, has lower cost, and can be complemented in a common chemical laboratory, and does not have environment pollution in the production process. Therefore, the tetrapyridylporphine bridged tetra-palladium complexes in a crossed structure can be used as novel potential antineoplastic drugs.
PURPOSE: A composition for anti-angiogenesis and inhibiting cancer growth comprising kringle domain protein TK1-2 and use thereof are provided, thereby inhibiting growth of endothelial cell, inhibiting angiogenesis and inhibiting growth of cancer, so that it can be useful for prevention of disease caused by angiogenesis and cancer. CONSTITUTION: The composition for anti-angiogenesis and inhibiting cancer growth comprises kringle domain protein TK1-2 derived from human tissue type plasminogen activator(t-PA) and having the amino acid sequence set forth in SEQ ID NO: 1. A recombinant E. coli expression plasmid pET-15b/TK1-2 produces the kringle domain protein TK1-2. The recombinant Pichia expression plasmids His-TK1-2/pPICZα-C and N-TK1-2/pPICZα-C produce the kringle domain protein TK1-2. A transformed E. coli produced by transforming E. coli with the plasmid pET-15b/TK1-2. A transformed Pichia sp. (KCTC 10415BP) produced by transforming Pichia with N-TK1-2/pPICZα-C produces the protein TK1-2.
Dioxolanes for perfumery use prepd. from glycols and carbonyl cpds.: Cpds. of formula (where A is -CH2-CH2- or -CH=CH-; R1 and R2 are H, 1-3C alkyl or together form a tri- or tetramethylene group; and if both A are -CH=CH-, one has trans- and the other cis- or trans-configuration and in case of a cis-trans configuration of both ethylenic bonds, both O atoms of dioxolane ring are in trans position) are used in perfumery and toilet or cosmetic articles and have a mushroom to wood or wood-amber fragrance. They are prepared by subjecting a glycol (where both OH are in trans position should the 2 ethylenic bonds exhibit a cis-trans configuration) to acid-catalysed ring-closure with R1R2C=O; or if saturated (I) is desired, by catalytically hydrogenating a cpd. (I) in which both A are -CH=CH-.